Introduction
VeriSee DR is an AI-assisted diagnostic software for diabetic retinopathy (DR) that identifies high-risk DR patients. Its core AI model has been trained from images labeled by retina specialists, and the software has been validated in a pivotal clinical trial against rigorous clinical reference standards. It leverages AI deep learning techniques to produce diagnosis results similar to that of professional ophthalmologists. It has been approved by Taiwan FDA, Thailand FDA, Indonesia MoH, and Philippines FDA. VeriSee DR is an effective solution that can shorten the screening process, increase the volume of screenings, improve the accuracy and consistency of the results, reduce costs, and improve patient outcomes.
Features / strengths
1. The first ophthalmic AI Software as a Medical Device (SaMD) approved by Taiwan FDA
2. Validated through a rigorous clinical trial
3. No ophthalmologist required
4. Real-time detection of DR lesions
5. Quick screening for high-risk cases
6. Integration with hospital information systems
Specification in detail
Supporting document
